

**CLEAVAGE OF
THE LOW-DENSITY LIPOPROTEIN-RECEPTOR-
RELATED PROTEIN (LRP)
BY MATRIX METALLOPROTEINASES (MMPs)
IN A NEURAL CELL MODEL:
IDENTIFICATION OF MULTIPLE
SOLUBLE LRP (sLRP) CLEAVAGE PRODUCTS.**

CHANTEL FITZSIMMONS

BSc (Biotechnology) (Hons)

**THESIS SUBMITTED FOR THE DEGREE OF
DOCTOR OF PHILOSOPHY**

JANUARY 2012

FACULTY OF HEALTH

UNIVERSITY OF NEWCASTLE

DECLARATION

I hereby certify the work embodied in this thesis contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying subject to the provisions of the Copyright Act 1968.

CHANTEL FITZSIMMONS

ACKNOWLEDGEMENTS

A PhD project is never the work of anyone alone. The contributions of many different people, in many different ways, have made this thesis possible. I would like to extend my appreciation to the following;

The most influential person during my PhD has been my supervisor, Dr Liz Milward. Liz's passion, work ethic, guidance and discipline have been indispensable to my growth as a scientist and as a person over the past four years. I would like to thank her for giving me the opportunity to undertake this PhD, for the opportunity to travel with her on her sabbatical to Johns Hopkins for six months and for providing financial support during that time. I would like to thank several members of Liz's family. Thanks to Karen Best for her timely rescue of me from a Washington Hostel and for giving me a place to stay close to Baltimore for those initial three months. Thanks to Phil and Laurie Best for being so welcoming, for allowing me to spend part of the summer at their beach house in Cape Hatteras, North Carolina and the opportunity to climb Mt Monadnock, New Hampshire in the fall. I would also like to thank the Huffs from upstate New York; Susie, Randy, Addison, Dylan and Miranda for opening their home to me, not only inviting me to stay during Thanksgiving and over New Year's, but also on my subsequent trips back to the states.

I would also like to thank the support, enthusiasm and assistance of the people I have met over the past four years. I am forever in debt to fellow PhD student Daniel Johnstone, whose assistance at all stages of my PhD, will always be greatly appreciated. My gratitude goes to Associate Professor Kathy Conant for the opportunity to work in her laboratory within the Department of Neurology and Neurosurgery, Johns Hopkins Hospital and to Dr Arkadiusz Szklarczyk (Arek) for his assistance and training during that time. Thanks to Jenny Ryu, I loved the atmosphere you created and it was a pleasure to work with you - the Conant lab wasn't the same without you! I would also like to thank Dr Monique Stins for her kindness during my stay and for inviting me to join her family for holidays and dinners. I would also like to thank Dr Rob Moir for the opportunity to stay with his family for a week in Boston and for inviting me to present my work to his laboratory in the Department of Neurology, Harvard Medical School.

Thanks to Adam Carroll who provided me with invaluable technical support and helping me to overcome many of the scientific difficulties that arose throughout my PhD. Thanks to Belinda Goldie, Sharon Hollins and Sarah Green for our insightful discussions, you really were my

‘situation solvers’. Thanks to Shahram Zandvakili, the time shared with you in the office was always refreshing for my mind and spirit.

My sincerest thank-you to Tek Bahadur Rana ‘Tekay’, our annual pilgrimage to Nepal to trek the Himalayas, our friendship and your philosophy helped me to hold on when I was getting a little crazy. I would also like to thank Aaron Wemer for his incredible friendship and cycling through Peru, Bolivia, Argentina and Chile with me for those four months when I needed a break from writing – it was an incredible journey, one I will never forget. I would like to thank the support of Doug Mungoven, not only for giving me a roof over my head for the past four years enabling me to focus on this project without financial constraints but for his continued friendship. I would also like to thank him for taking me canyoning when I have needed to periodically get away and jump off a cliff. Thank-you to my mother, Serena Williams and my sisters, Teanna Fitzsimmons and Rachelle Dodd, you encouraged me and were there in my most difficult moments and life choices - to you I dedicate this thesis. Finally I would like to thank my fiancé Ben Anfruns. You have stuck by me throughout my string of trips around the world, lost weekends and odd working hours. You encouraged me to complete this thesis when I wanted to give up and play soldier and if this work opens doors for us both, then I would gladly step through them with you, I love you sir.....

TABLE OF CONTENTS

1. INTRODUCTION.....	1
Overview	1
1.1. Endogenous Expression of LRP	4
1.2. Synthesis and Structure of LRP	5
1.3. Function of LRP	7
1.3.1. Lipid metabolism and cholesterol homeostasis	7
1.3.2. Protease Metabolism.....	9
1.3.3. Synaptic Plasticity.....	10
1.3.4. Virus and toxin endocytosis.....	12
1.3.5. The function of LRP in AD	13
1.3.5.1. AD pathology	13
1.3.5.2. APP processing	14
1.3.5.3. LRP and A β	15
1.3.6. Cellular Signal Transduction	17
1.4. Soluble LRP.....	19
1.4.1. Expression of sLRP	20
1.4.2. The function of sLRP.....	20
1.4.3. The mechanism of sLRP generation	21
1.5. Matrix Metalloproteinases (MMPs)	22
1.5.1. Structure and activation of MMPs	24
1.5.2. Endogenous MMPs Expression in the Nervous System	27
1.5.3. The Function of MMPs in the Nervous System.....	29
1.5.4. The Function of MMPs in Neurodegenerative Disease	30
1.6. Evidence for MMP-mediated cleavage of LRP to produce sLRP	33
1.7. Thesis Hypothesis and Aims	35
2. GENERAL MATERIALS AND METHODS	36
2.1. Cell Culture	36
2.1.1. Cell Lines.....	36
2.1.2. Maintenance and Cryopreservation of Cell Lines.....	37
2.1.2.1. Cell Passaging	37
2.1.2.2. Cryopreservation and Revival of Cell Lines	39
2.1.3. CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay	39

2.2.	Protein Analysis.....	40
2.2.1.	Isolation of sLRP- α and sLRP- β from conditioned medium.....	40
2.2.2.	DEAE-Sephacel ion-exchange chromatography	41
2.2.3.	Analysis of protein concentration of concentrated conditioned medium.....	41
2.2.4.	SDS-PAGE	42
2.2.5.	Western Immunoblotting	43
2.2.6.	Antibodies.....	44
3.	EXPRESSION OF SOLUBLE FORMS OF THE LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN (LRP) BY CNS-DERIVED CELLS.....	46
3.1.	INTRODUCTION	46
3.2.	MATERIALS AND METHODS	49
3.2.1.	Concentration of sLRP from SH-SY5Y conditioned medium by DEAE-sephacel ion-exchange chromatography.....	49
3.2.2.	Immunoprecipitation (IP).....	50
3.2.2.1.	<i>Sample Preparation</i>	50
3.2.2.2.	<i>Albumin/IgG removal</i>	50
3.2.2.3.	<i>Bead Preparation</i>	51
3.2.2.4.	<i>Pre-clearing</i>	51
3.2.2.5.	<i>Antibody incubation/formation of antibody-antigen complexes</i>	51
3.2.2.6.	<i>Precipitation</i>	52
3.2.2.7.	<i>Analysis by SDS-PAGE</i>	52
3.2.3.	N-terminal sequencing by automated Edman degradation and MALDI-ToF	53
3.3.	RESULTS.....	54
3.3.1.	Optimisation of Western immunoblotting conditions for the ~500 kDa sLRP α - chain fragment	54
3.3.1.1.	<i>Gel percentage</i>	54
3.3.1.2.	<i>Current and transfer time</i>	55
3.3.2.	Comparison of commercially available anti-LRP- α and anti-LRP- β antibodies to detect sLRP in SH-SY5Y conditioned medium.	56
3.3.3.	Detection of sLRP immunoreactive species in ‘serum-free’ supplements	59
3.3.3.1.	<i>Protein Sequencing – Edman Degradation</i>	61
3.3.4.	Short- term cell viability in serum-containing, serum-supplemented or serum-free media.....	63
3.3.5.	Endogenous sLRP expression under serum-supplemented conditions.....	65

3.3.6.	Comparison of the immunoprecipitation ability of commercially available anti-LRP- α and anti-LRP- β antibodies.....	68
3.3.6.1.	<i>Immunoprecipitation of SH-SY5Y conditioned medium using anti-LRP α-chain antibodies.....</i>	<i>69</i>
3.3.6.2.	<i>Immunoprecipitation of SH-SY5Y conditioned medium using anti-LRP β-chain antibodies.....</i>	<i>70</i>
3.3.7.	Immunoprecipitation of sLRP from the B27 supplement.....	72
3.3.7.1.	<i>Protein sequencing – Edman degradation and MALDI-ToF.....</i>	<i>73</i>
3.4.	DISCUSSION.....	75
4.	MATRIX METALLOPROTEINASE (MMP)-MEDIATED PROCESSING OF THE LOW- DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN (LRP) IN A NEURAL CELL MODEL: ENZYME INHIBITION.	79
4.1.	INTRODUCTION	79
4.2.	MATERIALS AND METHODS	81
4.2.1.	Cell Culture and Western Immunoblotting.....	81
4.2.2.	Gelatin Zymography	81
4.2.2.1.	<i>Sample Preparation</i>	<i>81</i>
4.2.2.2.	<i>Zymogram Development</i>	<i>82</i>
4.2.2.3.	<i>Zymogram Visualization</i>	<i>82</i>
4.2.3.	Reverse Gelatin Zymography	82
4.2.4.	Effect of synthetic MMP inhibitors on sLRP expression in vitro.....	83
4.2.5.	Statistical Analysis.....	85
4.3.	RESULTS.....	86
4.3.1.	Effect of MMP inhibitors on PC12 sLRP expression.	86
4.3.2.	Investigation of MMP-2 and MMP-9 activity in cell culture media and supplements.	86
4.3.3.	Investigation of TIMP activity in cell culture media and supplements.	87
4.3.4.	Time and dose-dependent cytotoxicity during MMP inhibitor treatment.....	88
4.3.5.	Inhibition of sLRP expression <i>in vitro</i> using the SH-SY5Y cell model	90
4.3.5.1.	<i>Effect of MMP inhibition on sLRP expression.....</i>	<i>91</i>
4.3.6.	Endogenous MMP and TIMP levels in the SH-SY5Y cell model.....	93
4.3.6.1.	<i>Endogenous MMP levels in conditioned medium: gelatin zymography</i>	<i>94</i>
4.3.6.2.	<i>Endogenous MMP levels in cell lysate: Western immunoblotting</i>	<i>94</i>
4.3.6.3.	<i>Endogenous TIMP activity in conditioned medium: reverse zymography.....</i>	<i>95</i>

4.4.	DISCUSSION.....	97
5.	LRP AND MMP GENE SILENCING BY RNA INTERFERENCE (RNAi)	101
5.1.	INTRODUCTION	101
5.2.	MATERIALS AND METHODS	109
5.2.1.	Cell Culture and Western Immunoblotting.....	109
5.2.2.	Gene silencing using RNA interference technology.....	109
5.2.2.1.	<i>Co-transfection of SH-SY5Y cells with Stealth siRNATM and pEGFP- N1 plasmid using Lipofectamine 2000.....</i>	<i>109</i>
5.2.2.2.	<i>Stealth siRNATM Target Sequences</i>	<i>110</i>
5.2.2.3.	<i>Fluorescent Microscopy.....</i>	<i>111</i>
5.2.2.4.	<i>RNA Extraction using TRIzol Reagent.....</i>	<i>111</i>
5.2.2.4.1.	<i>Cell Lysis.....</i>	<i>111</i>
5.2.2.4.2.	<i>Separation of Macromolecular Species</i>	<i>112</i>
5.2.2.4.3.	<i>RNA Precipitation.....</i>	<i>113</i>
5.2.2.4.4.	<i>RNA quality and concentration.....</i>	<i>113</i>
5.2.2.5.	<i>Reverse Transcription of RNA.....</i>	<i>113</i>
5.2.3.	Real Time PCR Primer Design	114
5.2.4.	Real Time PCR	114
5.2.5.	Statistical Analysis.....	115
5.3.	RESULTS.....	116
5.3.1.	Optimisation of transfection parameters	116
5.3.1.1.	<i>Transfection medium and seeding density</i>	<i>116</i>
5.3.1.1.1.	<i>Cell viability.....</i>	<i>118</i>
5.3.1.1.2.	<i>Transfection efficiency</i>	<i>120</i>
5.3.1.1.3.	<i>Gene knockdown</i>	<i>122</i>
5.3.1.2.	<i>Transfection time.....</i>	<i>123</i>
5.3.1.2.1.	<i>Cell viability.....</i>	<i>124</i>
5.3.1.2.2.	<i>Transfection efficiency</i>	<i>125</i>
5.3.1.2.3.	<i>Gene knockdown</i>	<i>126</i>
5.3.2.	MMP siRNA specificity	128
5.3.3.	LRP gene silencing using RNA interference	128
5.3.3.1.	<i>Quantitative real time RT-PCR analysis of LRP gene knockdown</i>	<i>129</i>
5.3.3.2.	<i>Endogenous sLRP-α expression after LRP gene silencing.....</i>	<i>129</i>
5.3.3.3.	<i>Endogenous sLRP-β expression after LRP gene silencing</i>	<i>131</i>

5.3.4.	The effect of gel percentage in detecting LRP- β	132
5.3.5.	MMP-2 gene silencing using RNA interference.....	134
5.3.5.1.	<i>Quantitative real time RT-PCR analysis of MMP-2 gene knockdown</i>	134
5.3.5.2.	<i>Endogenous MMP-2 expression after MMP-2 gene silencing</i>	135
5.3.5.2.1.	<i>Gelatin zymography</i>	135
5.3.5.2.2.	<i>Western Immunoblotting</i>	136
5.3.5.3.	<i>Endogenous sLRP-α expression after MMP-2 gene silencing</i>	137
5.3.5.4.	<i>Endogenous sLRP-β expression after MMP-2 gene silencing</i>	138
5.3.6.	MMP-9 gene silencing using RNA interference.....	140
5.3.6.1.	<i>Quantitative real time RT-PCR analysis of MMP-9 gene knockdown</i>	140
5.3.6.2.	<i>Endogenous MMP-9 expression after MMP-9 gene silencing</i>	141
5.3.6.2.1.	<i>Gelatin zymography</i>	141
5.3.6.2.2.	<i>Western Immunoblotting</i>	142
5.3.6.3.	<i>Endogenous sLRP-α expression after MMP-9 gene silencing</i>	143
5.3.6.4.	<i>Endogenous sLRP-β expression after MMP-9 gene silencing</i>	145
5.3.7.	MT1-MMP gene silencing using RNA interference.....	147
5.3.7.1.	<i>Quantitative real time RT-PCR analysis of MT1-MMP gene knockdown</i>	147
5.3.7.2.	<i>Endogenous MT1-MMP expression after MT1-MMP gene silencing</i>	148
5.3.7.2.1.	<i>Western Immunoblotting</i>	148
5.3.7.3.	<i>Endogenous sLRP-α expression after MT1-MMP gene silencing</i>	148
5.3.7.4.	<i>Endogenous sLRP-β expression after MT1-MMP gene silencing</i>	150
5.4.	DISCUSSION.....	152
6.	FINAL DISCUSSION	164
7.	REFERENCES	172

LIST OF FIGURES

FIGURE 1.1 EXPRESSION OF LRP IN MOUSE BRAIN.....	4
FIGURE 1.2 THE STRUCTURE AND LIGAND BINDING DOMAINS OF LRP.	6
FIGURE 1.3 STRUCTURE-DEPENDENT SUBGROUPING OF THE MATRIX METALLOPROTEINASES (MMPS).....	25
FIGURE 1.4 MMP CATALYTIC DOMAIN.....	26
FIGURE 1.5 EXPRESSION OF MMP-2 IN THE MOUSE BRAIN.....	28
FIGURE 1.6 EXPRESSION OF MMP-9 IN THE MOUSE BRAIN.....	28
FIGURE 1.7 EXPRESSION OF MT1-MMP IN THE MOUSE BRAIN.....	29
FIGURE 3.1 EFFECT OF GEL PERCENTAGE ON SLRP- α DETECTION.	54
FIGURE 3.2 EFFECT OF CURRENT AND TRANSFER TIME ON SLRP- α DETECTION.....	56
FIGURE 3.3 SCHEMATIC OF THE EPITOPES RECOGNISED BY THE COMMERCIALY AVAILABLE ANTI-LRP ANTIBODIES.	57
FIGURE 3.4 THE ABILITY OF COMMERCIAL ANTI-LRP- α ANTIBODIES TO DETECT LRP IMMUNOREACTIVITY IN CONDITIONED MEDIUM..	57
FIGURE 3.5 THE ABILITY OF COMMERCIAL ANTI-LRP- β ANTIBODIES TO DETECT LRP IMMUNOREACTIVITY IN CONDITIONED MEDIUM..	58
FIGURE 3.6 ENDOGENOUS SLRP IN THE ‘SERUM-FREE’ B27 SUPPLEMENT.	60
FIGURE 3.7 SEQUENCE HOMOLOGY BETWEEN LRP-1 AND A ~65 KDA PROTEIN ISOLATED FROM B27..	61
FIGURE 3.8 SEQUENCE HOMOLOGY BETWEEN FETUIN AND A ~65 KDA PROTEIN ISOLATED FROM B27.	62
FIGURE 3.9 EFFECT OF SERUM DEPRIVATION ON CELL VIABILITY..	64
FIGURE 3.10 PHASE CONTRAST MICROSCOPE IMAGES OF SH-SY5Y CELLS 24 H AFTER SERUM DEPRIVATION.	65
FIGURE 3.11 ENDOGENOUS SLRP- α EXPRESSION PRODUCTION OVER TIME.	66
FIGURE 3.12 ENDOGENOUS SLRP- β EXPRESSION PRODUCTION OVER TIME.	67
FIGURE 3.13 ENDOGENOUS SLRP- α EXPRESSION <i>IN VITRO</i> : IMMUNOPRECIPITATION..	69
FIGURE 3.14 ENDOGENOUS SLRP- β EXPRESSION <i>IN VITRO</i> : IMMUNOPRECIPITATION..	71
FIGURE 3.15 ENDOGENOUS SLRP IN THE ‘SERUM-FREE’ B27 SUPPLEMENT.....	72

FIGURE 3.16 SEQUENCE HOMOLOGY BETWEEN ALBUMIN AND A ~65 KDA PROTEIN ISOLATED FROM B27.	74
FIGURE 4.1 INVESTIGATION OF MMP-2 AND MMP-9 ACTIVITY IN CELL CULTURE MEDIA AND SUPPLEMENTS.	87
FIGURE 4.2 INVESTIGATION OF TIMP ACTIVITY IN CELL CULTURE MEDIA AND SUPPLEMENTS.....	88
FIGURE 4.3 TIME AND DOSE-DEPENDENT CYTOTOXICITY AFTER MMP INHIBITOR TREATMENT.....	89
FIGURE 4.4 EFFECT OF MMP INHIBITORS ON SLRP IMMUNOREACTIVE SPECIES <i>IN</i> <i>VITRO</i>	91
FIGURE 4.5 ENDOGENOUS MMP ACTIVITY IN CELL CONDITIONED MEDIUM.	94
FIGURE 4.6 ENDOGENOUS MMP LEVELS IN THE CELL MODEL.....	95
FIGURE 4.7 ENDOGENOUS TIMP ACTIVITY IN CONDITIONED MEDIUM OVER 24 H....	96
FIGURE 5.1 THE RNA INTERFERENCE PATHWAY.....	102
FIGURE 5.2 RESTRICTION MAP OF THE PEGFP-N1 PLASMID.	110
FIGURE 5.3 DETECTION OF LRP IMMUNOREACTIVITY IN OPTI-MEM® REDUCED SERUM MEDIUM.	116
FIGURE 5.4 EFFECT OF TRANSFECTION MEDIUM ON CELL VIABILITY.	119
FIGURE 5.5 EFFECT OF TRANSFECTION MEDIUM ON TRANSFECTION EFFICIENCY..	120
FIGURE 5.6 EFFECT OF TRANSFECTION MEDIUM ON TRANSFECTION EFFICIENCY: FLUORESCENT MICROSCOPE IMAGES.....	121
FIGURE 5.7 EFFECT OF TRANSFECTION MEDIUM ON MT1-MMP GENE EXPRESSION.	122
FIGURE 5.8 SCHEMATIC REPRESENTATION OF VARIOUS TRANSFECTION TIMEPOINTS FOR ANALYSING THE EFFECT OF EXPOSURE TO TRANSFECTION REAGENTS ON CELL VIABILITY, TRANSFECTION EFFICIENCY AND GENE TRANSFER.	123
FIGURE 5.9 EFFECT OF TRANSFECTION TIME ON CELL VIABILITY.	124
FIGURE 5.10 EFFECTS OF TRANSFECTION TIME ON REPORTER GENE EXPRESSION AND TRANSFECTION EFFICIENCY..	125
FIGURE 5.11 EFFECT OF TRANSFECTION TIME ON TRANSFECTION EFFICIENCY: FLUORESCENT MICROSCOPE IMAGES.....	126
FIGURE 5.12 EFFECT OF TRANSFECTION TIME ON MT1-MMP GENE EXPRESSION.....	127

FIGURE 5.13 REAL TIME RT-PCR ANALYSIS OF LRP GENE EXPRESSION AFTER GENE SILENCING BY SIRNA.	129
FIGURE 5.14 EFFECT OF LRP GENE KNOCKDOWN ON SLRP- α EXPRESSION.....	131
FIGURE 5.15 EFFECT OF LRP GENE KNOCKDOWN ON SLRP- β EXPRESSION.	132
FIGURE 5.16 EFFECT OF GEL PERCENTAGE ON SLRP- β DETECTION.	133
FIGURE 5.17 REAL TIME RT-PCR ANALYSIS OF MMP-2 EXPRESSION IN SH-SY5Y CELLS AFTER GENE SILENCING BY SIRNA.....	134
FIGURE 5.18 EFFECT OF MMP-2 GENE KNOCKDOWN ON ENDOGENOUS MMP-2 ACTIVITY IN CELL CONDITIONED MEDIUM.....	135
FIGURE 5.19 EFFECT OF MMP-2 GENE KNOCKDOWN ON ENDOGENOUS MMP-2 EXPRESSION.....	136
FIGURE 5.20 EFFECT OF MMP-2 GENE SILENCING ON SLRP- α EXPRESSION.	137
FIGURE 5.21 EFFECT OF MMP-2 GENE SILENCING ON SLRP- β EXPRESSION.	139
FIGURE 5.22 REAL TIME RT-PCR ANALYSIS OF MMP-9 EXPRESSION IN SH-SY5Y CELLS AFTER GENE SILENCING BY SIRNA.....	141
FIGURE 5.23 EFFECT OF MMP-9 GENE KNOCKDOWN ON ENDOGENOUS MMP-9 ACTIVITY IN CELL CONDITIONED MEDIUM.....	142
FIGURE 5.24 EFFECT OF MMP-9 GENE KNOCKDOWN ON ENDOGENOUS MMP-9 ACTIVITY.....	142
FIGURE 5.25 EFFECT OF MMP-9 GENE KNOCKDOWN ON SLRP- α EXPRESSION.	144
FIGURE 5.26 EFFECT OF MMP-9 SILENCING ON SLRP- β EXPRESSION.	146
FIGURE 5.27 REAL TIME RT-PCR ANALYSIS OF MT1-MMP EXPRESSION IN SH-SY5Y CELLS AFTER GENE SILENCING BY RNAL.....	147
FIGURE 5.28 EFFECT OF MT1-MMP GENE KNOCKDOWN ON ENDOGENOUS MT1-MMP ACTIVITY.....	148
FIGURE 5.29 EFFECT OF MT1-MMP GENE KNOCKDOWN ON SLRP- α EXPRESSION.....	149
FIGURE 5.30 EFFECT OF MT1-MMP GENE SILENCING SLRP- β EXPRESSION..	151
FIGURE 5.31 HUMAN PROTEIN: Q07954. THE AMINO ACID SEQUENCE OF LRP.	155
FIGURE 5.32 PREDICTED MMP-2 CLEAVAGE MOTIFS WITHIN LRP (HUMAN LRP PROTEIN: Q07954).....	160
FIGURE 5.33 MECHANISMS OF LRP ECTODOMAIN SHEDDING AND SLRP PRODUCTION.	163

LIST OF TABLES

TABLE 1.1 LDL RECEPTOR SUPERFAMILY.....	2
TABLE 1.2 LIGANDS RECOGNISED BY LRP.....	3
TABLE 1.3 MMP FAMILY MEMBERS WITH THEIR MAJOR SUBSTRATES AND MODULATORS.	23
TABLE 2.1 SUMMARY OF THE PRIMARY AND SECONDARY ANTIBODIES USED IN THE STUDY.	45
TABLE 4.1 PROTEASE INHIBITORS USED IN THE STUDY..	84
TABLE 5.1 SIRNA DUPLEX SEQUENCES	110
TABLE 5.2 THERMAL CYCLER INCUBATION STEPS FOR REVERSE TRANSCRIPTION..	114
TABLE 5.3 PRIMER SEQUENCES FOR MRNA QUANTIFICATION BY REAL TIME PCR.	114
TABLE 5.4 REAL TIME PCR CYCLING CONDITIONS.....	115
TABLE 5.5 TRANSFECTION MEDIUM COMBINATIONS.....	118
TABLE 5.6 SIRNA SPECIFICITY	128
TABLE 5.7 PREDICTED SLRP SPECIES AFTER MMP-2 CLEAVAGE..	161
TABLE 5.8 CLEAVAGE SITE MOTIFS FOR MMP-2, MMP-9 AND MT1-MMP.....	162

LIST OF EQUATIONS

EQUATION 2.1 $RV = V/TC \times 100$	38
EQUATION 2.2 $C = (NC*2)*(SV)*(DF)$	38
EQUATION 5.1 $TE = T/TC \times 100$	111
EQUATION 5.2 $[RNA \mu G/ML] = A_{260} \times RNA \text{ EXTINCTION COEFFICIENT} \times DILUTION$ FACTOR.....	113
EQUATION 5.3 $RELATIVE \text{ EXPRESSION} = 2^{(-\Delta CT)}$	115

PUBLICATIONS ARISING FROM THIS THESIS

PEER REVIEWED PUBLICATIONS:

1. **Fitzsimmons, C.,** Johnstone, D., Parsons, C.H., Conant, K., Milward, E.A. ‘Soluble lipoprotein receptor-related protein (sLRP) immunoreactive species in cell culture media and serum replacement supplements’ (in preparation).

CONFERENCE PUBLICATION:

1. **Fitzsimmons, C.,** Johnstone, D., Conant, K., Milward, E.A. ‘Cleavage of the low-density lipoprotein receptor-related protein (LRP) by matrix metalloproteinases (MMPs) in the CNS’, The Australian Society for Medical Research (ASMR) XVI NSW Scientific Meeting, Sydney, Australia (2007).
2. **Fitzsimmons, C.,** Johnstone, D., Conant, K., Milward, EA. ‘Soluble lipoprotein receptor-related protein (sLRP) immunoreactive species in cell culture media and serum replacement supplements’, The Australian Society for Medical Research (ASMR) XVII NSW Scientific Meeting, Sydney, Australia (2008).
3. **Fitzsimmons, C.,** Johnstone, D., Conant, K., Milward, E.A. ‘Matrix metalloproteinase (MMP)-mediated cleavage of the low-density lipoprotein receptor-related protein (LRP) in the CNS to generate soluble LRP (sLRP) species with neurodegenerative potential’, Alzheimer’s Association International Conference on Alzheimer’s Disease and Related Disorders (ICAD), Chicago (2008).
4. **Fitzsimmons, C.,** Johnstone, D., Conant, K., Milward, EA. ‘Matrix metalloproteinases (MMP)-mediated cleavage of the low-density lipoprotein receptor-related protein (LRP)’. The Australian Society for Medical Research (ASMR) XVIII NSW Scientific Meeting, Sydney, Australia (2009).

ORAL PRESENTATIONS:

1. Invited by A/Prof. Robert D Moir, Harvard Medical School, Mass. General Institute for Neurodegenerative Disease (MIND Institute), Department of Neurology, Massachusetts General Hospital, Charleston, MA 02129. **Fitzsimmons, C.**, Johnstone, D., Conant, K., Milward, E.A. 'Soluble forms of LRP' (2006).

LIST OF COMMONLY USED ABBREVIATIONS

A1AT	α 1-Antitrypsin
α 2M	Alpha-2-macroglobulin
α 2M*	Activated alpha-2-macroglobulin
A β	Amyloid beta
AD	Alzheimer's disease
ADAM	a disintegrin and metalloproteinase
AEBSF	4-(2-aminoethyl) benzenesulfonyl fluoride
ALS	Amyotrophic lateral sclerosis
APOE	Apolipoprotein E
APOER2	Apolipoprotein E receptor 2
APP	Amyloid precursor protein
APS	Ammonium persulfate
BACE-1	β -site APP-cleaving enzyme 1
BeWo	Choriocarcinoma cell line, human
BBB	Blood brain barrier
BCA	Bicinchoninic acid
BHK	Baby hamster kidney
BMP	Bone morphogenic protein
BSA	Bovine serum albumin
CA1	Hippocampal subregion 1
Ca ¹⁺	Cuprous ion
Ca ²⁺	Cupric ion
CaCl ₂	Calcium chloride
CBX	Cerebellar cortex
CCL2	Chemokine (C-C motif) ligand 2
CD91	Cluster of differentiation 91
cDNA	Complementary DNA
CED 1	<i>Caenorhabditis elegans</i> death protein 1
CHO	Chinese hamster ovary
CNS	Central nervous system
C1r	Complement C1r subcomponent

CSF	Cerebral spinal fluid
DAB-1	Disabled-1
DEAE	Diethylaminoethyl cellulose
DMEM	Dulbecco's modified eagle's medium
DMSO	Dimethyl sulphoxide
DNA	Deoxyribonucleic acid
dNTP	Deoxynucleotide triphosphate
ECL ⁺	Enhanced chemiluminescence solution
ECM	Extracellular matrix
EDTA	Ethylenediaminetetra-acetic acid
EGF	Epidermal growth factor
ER	Endoplasmic reticulum
FAD	Familial form of AD
FBS	Foetal bovine serum
FDA	Food and Drug Administration
FGFs	Fibroblast growth factors
FLIM	Fluorescence lifetime imaging microscopy
FRET	Fluorescence resonance energy transfer
GFP	Green fluorescent protein
GPI	glycosylphosphatidylinositol
HBBS	Hanks' balanced salt solution
HB-EGF	Heparin-binding epidermal growth factor
HCl	Hydrochloric acid
HEK 293	Embryonic kidney cell line, human
HEPES	N-2-Hydroxyethyl piperazine-N-2-ethane sulfonic acid
HepG2	Hepatocellular carcinoma, human
HIV	Human immunodeficiency virus
HPF	Hippocampal formation
HRP	Horseradish peroxidase
HRV2	Human rhinovirus-2
HSP	Heat shock protein
HSPG	Heparin sulfate proteoglycan
HT1080	Fibrocarcinoma cell line, human
IGFBP-5	Insulin-like growth factor binding protein 5

IgG	Immunoglobulin G
IL-1 β	Interleukin-1 β
IL-6	Interleukin-6
IL-6 α	Interleukin 6 receptor alpha subunit
iNOS	Inducible nitric oxide synthase
IP	Immunoprecipitation
ISH	<i>in situ</i> hybridization
JIP	JNK (Jun N-terminal Kinase) interacting protein
KA	Kainate
KD	Knockdown
kDa	Kilodalton
KO	Knockout
KPI	Kunitz protease inhibitor domain.
LDL	Low-density lipoprotein
LDLR	Low-density lipoprotein receptor
LIF	Leukaemia inhibitory factor
L-LTP	Late-phase long term potentiation
LPS	Lipopolysaccharide
LRP	Low-density lipoprotein receptor-related protein 1
LRP ICD	LRP intracellular domain
LTP	Long term potentiation
mAb	Monoclonal antibody
MafB	v-maf Musculoaponeurotic fibrosarcoma oncogene homologue
MALDI-ToF	Matrix-assisted laser desorption/ionisation-time of flight mass spectrometry
MAP	Mitogen-activated protein
MC7	Recombinant breast carcinoma cell lines, human
MCP-1	Monocyte chemoattractant protein-1
MEF	Mouse embryonic fibroblast
MegF7	Multiple epidermal growth factor-containing protein 7
MEM	Minimum essential medium
MES	2 (N-morpholino) ethanesulfonic acid
MMP	Matrix metalloproteinase
MOPS	n-(3-sulfopropyl morpholine) propanesulfonic acid
mRNA	Messenger RNA

MS	Multiple sclerosis
MT-MMP	Membrane-type matrix metalloproteinase
MTS	3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
NaCl	Sodium chloride
NaPO ₄	Sodium phosphate
Neurobasal+N2	Neurobasal medium supplemented with N2
NMDAR	N-methyl-d-aspartic acid receptor
NOS	Nitric acid synthase
Notch-3	Neurogenic locus notch homolog protein 3
NPxY	A tetra-amino-acid motif
NTC	Non-transfected control
OD	Optical density
pAb	Polyclonal antibody
PAI-1	Plasminogen activator inhibitor 1
PBS	Phosphate buffered saline
PBS-T	Phosphate buffered saline + 0.1% Tween 20
PC12	Pheochromocytoma
PCR	Polymerase chain reaction
PDGF	Platelet-derived growth factor
PE	<i>Pseudomonas exotoxin A</i>
pI	isoelectric point
PS1	Presenilin protein 1
PS2	Presenilin protein 2
PSD-95	Postsynaptic density protein-95
PTB	Phosphotyrosine binding
PTC	<i>pseudotumour cerebri</i>
PVDF	Polyvinylidene fluoride
RAGE	Receptor for advanced glycation end products
RAP	Receptor-associated protein
RISC	Argonaut-dependent RNA-induced silencing complex
RIP	Regulated intramembraneous proteolysis
RNA	Ribonucleic acid
RNAi	RNA interference

PrPc	Cellular prion protein
RT	Room temperature
RT-PCR	Reverse transcription polymerase chain reaction
SAP	Sphingolipid activator protein
SDS	Sodium dodecyl sulfate
SDS-PAGE	Sodium dodecyl sulfate polyacrylamide gel electrophoresis
Shh	Sonic hedgehog
SHRSP	Stroke-prone spontaneously hypersensitive rats
SH-SY5Y	Neuroblastoma cell line, human
siRNA	Short interfering RNA
sLRP	Soluble LRP
SORLA	Sortilin-related receptor, low-density lipoprotein receptor class A repeat-containing protein
SREC1	Scavenging receptor 1 of endothelial cells
SYBR	Synergy Brands
TAPI-1	TNF- α Protease Inhibitor-1
TACE	TNF- α converting enzyme
TAT	Transactivator of Transcription
TEMED	<i>NNN'</i> N'-tetramethylethylene-diamine
TGF- α	Transforming growth factor- α
TGF- β	Transforming growth factor- β
TIMP	Tissue inhibitor of metalloproteinase
TNF- α	Tumour necrosis factor- α
TNFR1	Tumour necrosis factor receptor-1
tPA	Tissue plasminogen activator
TSP	Thrombospondin
uPA	Urokinase plasminogen activator
uPAR	Urokinase plasminogen activator receptor
UV	Ultraviolet
VLDL	Very low-density lipoprotein
WB	Western immunoblot
WKY	Wistar Kyoto rats
Wnt	Wingless-int

ABSTRACT

The low-density lipoprotein receptor-related protein (LRP) is a large transmembrane scavenger and signalling receptor. Binding over 50 ligands in the extracellular environment LRP has a wide range of physiological and pathological functions. For example, in the brain, LRP ligands include the Alzheimer's disease amyloid beta peptide (A β) and apolipoprotein E (APOE). Cellular LRP can be cleaved by proteolytic enzymes to generate soluble fragments (sLRP). Some sLRP fragments retain one or more ligand-binding domains and may exert antagonistic effects on cellular LRP. Previous studies using broad spectrum matrix metalloproteinase (MMP) inhibitors suggest one or more MMPs may be implicated in sLRP generation. The MMPs are a group of zinc-dependent endopeptidases that are best characterised for their ability to degrade extracellular matrix (ECM) proteins and remodel existing cell-matrix boundaries.

The broad hypothesis underlying this project is that MMPs can contribute to the generation of sLRP species in a cellular system relevant to the CNS.

The SH-SY5Y cell line, derived from a human neuroblastoma, was established as a useful cell model. The cell line was found to endogenously release several putative sLRP α -chain (~500 kDa) and β -chain (~275 kDa, ~150-100kDa, ~85 kDa, ~75 kDa, ~65 kDa and ~55 kDa) species *in vitro*. While developing this model under serum-free conditions, substantial quantities of sLRP immunoreactivity were detected in the B27 supplement that was not listed among the components. The unrecognised presence of sLRP, and possibly other undefined serum proteins, has the potential to introduce experimental artefacts and interfere with experimental results and interpretation in cell culture studies involving LRP or any of its ligands. Neurobasal medium supplemented with N2 was identified as an alternative serum-free medium suitable for investigating sLRP production *in vitro*.

Treatment with synthetic MMP inhibitors reduced the release of soluble LRP species into the culture medium. It was found that sLRP is generated primarily by MMP-2 in this system and possibly also by MMP-9 dependent activity. The data provided evidence that LRP contains at least two MMP cleavage sites: at least one located within the β -chain and one in the α -chain.

N-terminal sequencing using Edman degradation and MALDI-ToF did not generate sequence data due to N-terminal blockage. However all the soluble species, with the exception of the ~75 kDa and ~65 kDa species, were no longer detectable after RNA interference was used to silence LRP gene function. This confirms that these species are soluble forms of cellular LRP. This also shows that the ~75 kDa and ~65 kDa species are not in fact derived from LRP.

RNA interference was also utilised as an alternative approach to reduce the levels of specific MMP transcripts within the cell model. In accordance with the MMP inhibitor studies it was found that sLRP production is MMP-2 and MMP-9 mediated. As MT1-MMP is required for the activation of pro-MMP and potentially also pro-MMP-9, the effect of down-regulating MT1-MMP gene function was also investigated. Production of the major ~500 kDa sLRP- α species and the major ~85 kDa and ~55 kDa sLRP- β species was almost completely abolished, proving evidence that MT-MMP has important roles in sLRP generation in this system.

In summary, the findings presented within this thesis provide evidence for the first time that several sLRP species are endogenously produced in cells relevant to the CNS. Furthermore, data is also presented that identifies MT1-MMP, as well as MMP-2 and MMP-9, as the key matrix metalloproteinase able to affect sLRP production in a neural cell system. Understanding the mechanisms by which LRP is processed may help develop new treatment strategies for Alzheimer's disease or related neurodegenerative disorders.